Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (301-310 of 310) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 310 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
Therapeutic Advances in Medical Oncology|June 7, 2021
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 studyYen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2024
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced HypersensitivityChun-Bing Chen, Chuang-Wei Wang, Chun-Wei Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled TrialByoung Chul Cho, Weimin Li, Alexander I Spira, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
The Lancet. Respiratory Medicine|December 2, 2023
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort studyGee-Chen Chang, Chao-Hua Chiu, Chong-Jen Yu, et al.
Pageof 31

Showing results (301-310 of 310) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 310 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.
Therapeutic Advances in Medical Oncology|June 7, 2021
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 studyYen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2024
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced HypersensitivityChun-Bing Chen, Chuang-Wei Wang, Chun-Wei Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled TrialByoung Chul Cho, Weimin Li, Alexander I Spira, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
The Lancet. Respiratory Medicine|December 2, 2023
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort studyGee-Chen Chang, Chao-Hua Chiu, Chong-Jen Yu, et al.
Pageof 31